JS111

JS111 is a small-molecule drug developed by Suzhou Junjing BioSciences. Its targets are EGFR and MET (the sponsor names EGFR). The sponsor states: Oral EGFR tyrosine kinase inhibitor (capsule) targeting EGFR exon 19 deletion and L858R sensitising mutations in NSCLC, dosed once daily; an active metabolite (M546b) is also tracked. ClinicalTrials.gov describes the intervention as: In Phase I, approximately 3-12 subjects will be enrolled in each dose group (160 mg QD or 240 mg QD) and receive oral JS111 capsules once daily until any treatment discontinuation criteria are met. After all subjects have completed at least. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT06940401, plans to enrol 44 participants (actual) with primary completion expected 2028-07-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.